{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:16:47Z","timestamp":1790767007901,"version":"4.1.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The upregulation of B-cell lymphoma 2 (BCL2) and B-cell lymphoma\u2013extra large (BCL-XL), 2 proteins in the BCL2 family of proteins, leads to a disproportional expression of prodeath and prosurvival proteins in favor of leukemia survival, tumorigenesis, and chemoresistance. In different subsets of acute lymphoblastic leukemia (ALL), the proportion of these 2 proteins varies, and their potential as therapeutic targets needs detailed characterization. Here, we investigated BCL2 and BCL-XL, the genes that encode BCL2 and BCL-XL, and their expression differences between B-cell acute lymphoblastic leukemia (B-ALL) and T-cell ALL (T-ALL). We also evaluated the therapeutic potential of targeting these proteins with AZD0466, a novel drug-dendrimer conjugate of the BCL2\/BCL-XL inhibitor AZD4320, and with BCL2 inhibitor venetoclax (ABT-199). Gene expression and activity analyses supported by the protein expression patterns in ALL cell lines and primary samples demonstrated increased levels of BCL2 expression in B-ALL, with high sensitivity to venetoclax or AZD4320. In contrast, strong BCL-XL expression and sensitivity to dual BCL2\/BCL-XL inhibition was observed specifically in T-ALL samples. This observation was confirmed by BH3 profiling, demonstrating BCL2\/BCL-XL codependence in T-ALL and BCL2 dependence in B-ALL. In a mouse model of T-ALL, AZD0466 but not venetoclax reduced leukemic burden and prolonged survival without significant toxicities. Our findings therefore suggest that the novel dual BCL2\/BCL-XL inhibitor AZD0466 outperforms single BCL2 inhibition by venetoclax in T-ALL. These findings facilitate the translation of dual BCL2\/BCL-XL inhibitors into ALL clinical trials, either alone or in combination with standard-of-care chemotherapy and immune therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013423","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T21:59:55Z","timestamp":1732053595000},"page":"473-487","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Antileukemia efficacy of the dual BCL2\/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1058-878X","authenticated-orcid":false,"given":"Sankaranarayanan","family":"Kannan","sequence":"first","affiliation":[{"name":"1Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-6691","authenticated-orcid":false,"given":"Yizhen","family":"Li","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Children\u2019s Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China"},{"name":"4Department of Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-4798","authenticated-orcid":false,"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[{"name":"5Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1153-4894","authenticated-orcid":false,"given":"Sanaz","family":"Ghotbaldini","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang Tatarata","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"4Department of Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Li","sequence":"additional","affiliation":[{"name":"4Department of Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuChih","family":"Hsiao","sequence":"additional","affiliation":[{"name":"4Department of Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-0432","authenticated-orcid":false,"given":"Srividya","family":"Balachander","sequence":"additional","affiliation":[{"name":"6Bioscience, Oncology R&D, AstraZeneca, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2064-2273","authenticated-orcid":false,"given":"Courtney L.","family":"Andersen","sequence":"additional","affiliation":[{"name":"6Bioscience, Oncology R&D, AstraZeneca, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-4438","authenticated-orcid":false,"given":"Justin","family":"Cidado","sequence":"additional","affiliation":[{"name":"6Bioscience, Oncology R&D, AstraZeneca, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-4429","authenticated-orcid":false,"given":"Jiyang","family":"Yu","sequence":"additional","affiliation":[{"name":"5Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[{"name":"4Department of Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"7Department of Oncology, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"6","key":"2025032119370871400_bib1","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"2025032119370871400_bib2","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025032119370871400_bib3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/cas.12927","article-title":"Genetic abnormalities associated with acute lymphoblastic leukemia","volume":"107","author":"Yokota","year":"2016","journal-title":"Cancer Sci"},{"issue":"9","key":"2025032119370871400_bib4","doi-asserted-by":"crossref","first-page":"E245","DOI":"10.1002\/ajh.25896","article-title":"Outcome of adults with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"95","author":"Samra","year":"2020","journal-title":"Am J Hematol"},{"issue":"7","key":"2025032119370871400_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/cncr.33340","article-title":"Sequencing of novel agents in relapsed\/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Badar","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"2025032119370871400_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032119370871400_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","article-title":"T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies","volume":"2","author":"Cordo","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"15","key":"2025032119370871400_bib8","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"2025032119370871400_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ"},{"issue":"9","key":"2025032119370871400_bib10","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"40","key":"2025032119370871400_bib11","doi-asserted-by":"crossref","first-page":"12480","DOI":"10.1073\/pnas.1516208112","article-title":"Selective targeting of JAK\/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2025032119370871400_bib12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of T-ALL","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood"},{"key":"2025032119370871400_bib13","first-page":"100756","article-title":"Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines","volume":"22","author":"Abdul Rahman","year":"2020","journal-title":"Biochem Biophys Rep"},{"issue":"11","key":"2025032119370871400_bib14","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","article-title":"Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid","volume":"13","author":"Andreeff","year":"1999","journal-title":"Leukemia"},{"issue":"10","key":"2025032119370871400_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2025032119370871400_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/10428194.2020.1861278","article-title":"Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax","volume":"62","author":"Marques-Piubelli","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025032119370871400_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","article-title":"MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents","volume":"13","author":"Bolomsky","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"24","key":"2025032119370871400_bib18","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","article-title":"AZD4320, a dual inhibitor of Bcl-2 and Bcl-x(L), induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia","volume":"26","author":"Balachander","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025032119370871400_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00127","article-title":"First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia","volume":"2","author":"Numan","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"2025032119370871400_bib20","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/bloodadvances.2022007728","article-title":"BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia","volume":"7","author":"Olesinski","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025032119370871400_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3324\/haematol.2015.136366","article-title":"Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis","volume":"102","author":"Herold","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2025032119370871400_bib22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL","volume":"31","author":"Tasian","year":"2017","journal-title":"Leukemia"},{"key":"2025032119370871400_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4939-8861-7_4","article-title":"BH3 profiling: a functional assay to measure apoptotic priming and dependencies","volume":"1877","author":"Fraser","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2025032119370871400_bib24","doi-asserted-by":"crossref","first-page":"a008714","DOI":"10.1101\/cshperspect.a008714","article-title":"Mechanisms of action of Bcl-2 family proteins","volume":"5","author":"Shamas-Din","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"2025032119370871400_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","article-title":"Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics","volume":"2","author":"Letai","year":"2002","journal-title":"Cancer Cell"},{"issue":"3","key":"2025032119370871400_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.14684","article-title":"Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment","volume":"178","author":"Vogler","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"2025032119370871400_bib27","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2025032119370871400_bib28","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","article-title":"A\u00a0phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025032119370871400_bib29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/10428194.2020.1845332","article-title":"Safety and efficacy of navitoclax, a BCL-2 and BCL-X(L) inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study","volume":"62","author":"de Vos","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025032119370871400_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun Biol"},{"issue":"3","key":"2025032119370871400_bib31","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Kojima","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2025032119370871400_bib32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1172\/JCI30235","article-title":"Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase","volume":"117","author":"Iwamoto","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2025032119370871400_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"2","key":"2025032119370871400_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"key":"2025032119370871400_bib35","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/2159-8290.CD-21-0145","article-title":"Enhancer Hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia","volume":"11","author":"Montefiori","year":"2021","journal-title":"Cancer Discov"},{"issue":"12","key":"2025032119370871400_bib36","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1093\/bioinformatics\/bty907","article-title":"SJARACNe: a scalable software tool for gene network reverse engineering from big data","volume":"35","author":"Khatamian","year":"2019","journal-title":"Bioinformatics"},{"issue":"2","key":"2025032119370871400_bib37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq--a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"issue":"3","key":"2025032119370871400_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","article-title":"Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia","volume":"2","author":"Gocho","year":"2021","journal-title":"Nat Cancer"},{"issue":"7708","key":"2025032119370871400_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-018-0177-0","article-title":"Hippo\/Mst signalling couples metabolic state and immune function of CD8alpha(+) dendritic cells","volume":"558","author":"Du","year":"2018","journal-title":"Nature"},{"issue":"8","key":"2025032119370871400_bib40","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.3593","article-title":"Functional characterization of somatic mutations in cancer using network-based inference of protein activity","volume":"48","author":"Alvarez","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"2025032119370871400_bib41","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41467-018-03843-3","article-title":"Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm","volume":"9","author":"Ding","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"2025032119370871400_bib42","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"4","key":"2025032119370871400_bib43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/1541-7786.MCR-20-0586","article-title":"The heme-regulated inhibitor pathway modulates susceptibility of poor prognosis B-lineage acute leukemia to BH3-mimetics","volume":"19","author":"Smith","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"Pt 3","key":"2025032119370871400_bib44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1042\/BJ20050433","article-title":"Alamethicin permeabilizes the plasma membrane and mitochondria but not the tonoplast in tobacco (Nicotiana tabacum L. cv Bright Yellow) suspension cells","volume":"389","author":"Matic","year":"2005","journal-title":"Biochem J"},{"issue":"1","key":"2025032119370871400_bib45","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1038\/s41467-022-30396-3","article-title":"Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia","volume":"13","author":"Baran","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"2025032119370871400_bib46","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/1535-7163.MCT-18-0706","article-title":"Antileukemia effects of notch-mediated inhibition of oncogenic PLK1 in B-cell acute lymphoblastic leukemia","volume":"18","author":"Kannan","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2025032119370871400_bib47","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/antiox11040717","article-title":"Targeting the NRF2\/HO-1 antioxidant pathway in FLT3-ITD-positive AML enhances therapy efficacy","volume":"11","author":"Kannan","year":"2022","journal-title":"Antioxidants"},{"issue":"2","key":"2025032119370871400_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7380","key":"2025032119370871400_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"15","key":"2025032119370871400_bib50","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2025032119370871400_bib51","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2025032119370871400_bib52","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/leu.2013.377","article-title":"BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines","volume":"28","author":"Anderson","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2025032119370871400_bib53","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025032119370871400_bib54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"6","key":"2025032119370871400_bib55","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2025032119370871400_bib56","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/10428194.2021.1910684","article-title":"CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1\/2 and BCL2 inhibition through CNS infiltration","volume":"62","author":"Walker","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2025032119370871400_bib57","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"issue":"1","key":"2025032119370871400_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to BCL-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"2025032119370871400_bib59","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in high-risk B-ALL","volume":"4","author":"Moujalled","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/473\/2354516\/blooda_adv-2024-013423-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/473\/2354516\/blooda_adv-2024-013423-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:12:12Z","timestamp":1742587932000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/3\/473\/526010\/Antileukemia-efficacy-of-the-dual-BCL2-BCL-XL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013423","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]}}}